Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer.
Levamisole has been used in a wide array of clinical research and treatment settings over the past two decades, ranging from such diseases as helminthic infestations to various autoimmune diseases. Numerous preclinical evaluations and clinical trials with levamisole in the cancer arena have been sponsored by the National Cancer Institute and other agencies worldwide with the hopes of demonstrating anticancer activity. Trials in advanced breast cancer, lung cancer, colorectal cancer, melanoma, and lymphoproliferative diseases have generally been negative or inconclusive. However, there is some indication that levamisole may be useful by itself as an adjuvant therapy for resected melanoma; recently it has been shown to be effective in combination with fluorouracil (5-FU) as adjuvant therapy for tumor-node-metastasis (TNM) stage III (Dukes' C) colon carcinoma. In the aggregate, the past 20 years of clinical experience with levamisole has resulted in as many questions as answers. However, further testing of the anticancer activity of levamisole can be expected in clinical research trials over the next few years. Hopefully, these future trials will include studies of the mechanisms of action of this agent.
Investigational Drug Branches, National Cancer Institute, National Institute of Health, Bethesda, MD 20892.
H C
HC
Stevenson
I
I
Green
J M
JM
Hamilton
B A
BA
Calabro
D R
DR
Parkinson
D000818:Animals; D004347:Drug Interactions; D005544:Forecasting; D006801:Humans; D007109:Immunity / Q000187:drug effects*; D066298:In Vitro Techniques; D007978:Levamisole / Q000494:pharmacology* / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology
D007978:Levamisole